title: Isotretinoin differs from other synthetic retinoids in its modulation of human cellular retinoic acid binding protein (CRABP).
abstract: Isotretinoin differs from acitretin and Ro137410 by its striking sebostatic effect in acne after oral, but not topical, administration. The reason for this is not yet understood. Previous studies indicate that cellular retinoic acid binding protein (CRABP) might be implicated in the action of synthetic retinoids. We, therefore, compared the three retinoids for their ability to increase epidermal CRABP levels after systemic and topical treatment. Oral treatment with acitretin and Ro137410 led to a striking increase of epidermal CRABP (from 2.6 +/- 0.9 to 16.2 +/- 2.9, P less than 0.004 and from 2.5 +/- 1.2 to 21.5 +/- 3.4 pmol/mg protein, P less than 0.004, respectively), while isotretinoin failed to induce a comparable rise (3.2 +/- 1.6 before and 3.7 +/- 0.7 pmol/mg protein after treatment), although it displayed in all patients a striking sebostatic effect. After topical application, the increase of CRABP was comparable for all three compounds. The interaction of isotretinoin with the epidermis seems to be different from other synthetic retinoids only after systemic treatment, a finding that parallels clinical observations.
authors.affiliation: Clinique de Dermatologie, Hôpital Cantonal Universitaire, Geneva, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Hirschel-Scholz
authors.forename: G
authors.initials: G
authors.lastname: Siegenthaler
authors.forename: J H
authors.initials: JH
authors.lastname: Saurat
mesh_terms: D017255:Acitretin; D000152:Acne Vulgaris / Q000188:drug therapy*; D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D001565:Benzoates / Q000627:therapeutic use; D002352:Carrier Proteins / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018168:Receptors, Retinoic Acid; D012176:Retinoids / Q000627:therapeutic use; D012867:Skin / Q000378:metabolism; D013997:Time Factors; D014212:Tretinoin / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D001565:Benzoates; D002352:Carrier Proteins; D018168:Receptors, Retinoic Acid; D012176:Retinoids; D014212:Tretinoin; C038864:4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid; D015474:Isotretinoin; D017255:Acitretin